Journal: Frontiers in Pharmacology
Article Title: MT2 receptor mediates melatonin-induced thermogenic program in human myoblasts: insights for circadian syndrome and diabesity treatment
doi: 10.3389/fphar.2025.1633326
Figure Lengend Snippet: Effect of melatonin on MT2 expression. (a) Densitometry quantification of MT2 amount in unsilenced and MTNR1B -silenced human myoblast. (b) Representative blot of MT2 expression. α-tubulin was used as loading control. All values are expressed as mean ± SD of three independent experiments in triplicate. A one-way ANOVA followed by Tukey’s post hoc test was performed for statistical analysis (* P < 0.05, Melatonin treated vs. Non-treated; # P < 0.05 and ## P < 0.01, siRNA MTNR1B vs. Scrambled negative control, siRNA C − ).
Article Snippet: The primary antibody was generated in goat against MT2 (cat#sc-13177, Santa Cruz Biotechnology, United States) and PGC1α (cat#SAB2500781, Sigma-Aldrich, Spain); in mice against Calcineurin (cat#H00005530-M03, Abnova, United States), SERCA2 (cat#S1439, Sigma-Aldrich, Spain), CaMKII (cat#SC-13141, Santa Cruz Biotechnology, United States), and P-CaMKII (cat#SC-32289, Santa Cruz Biotechnology, United States); and in rabbit against SLN (cat#MBS713457, MyBiosource, United States), SERCA1 (cat#SAB5701310, Sigma-Aldrich, Spain), AMPK (cat#SAB4502329, Sigma-Aldrich, Spain), and P-AMPK (cat#SAB4503754, Sigma-Aldrich, Spain); all diluted 1:1,000 in PBS-T with 10% blocking solution.
Techniques: Expressing, Control, Negative Control